Cytokinetics Incorporated (NASDAQ: CYTK) Receives FDA Approval for Myqorzo

Core Insights - Cytokinetics Incorporated has received FDA approval for Myqorzo (aficamten), a drug aimed at treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM), marking a significant milestone for the company [1][3][5] - The approval addresses a substantial medical need and aims to improve patients' functional capacity while alleviating symptoms [1][3][5] Financial Summary - Truist Financial has set a price target of $84 for CYTK, indicating a potential upside of approximately 24.76% from its trading price of $67.33 on December 22, 2025 [2][5] - The stock has shown a recent increase to $67.57, reflecting a 7.73% rise or $4.85, with a trading range today between $63.18 and $70.98 [2] - CYTK's market capitalization is approximately $8.04 billion, with a trading volume of 5,494,603 shares on the NASDAQ [4] Market Performance - The stock has experienced volatility, with a 52-week trading range between $29.31 and $70.98, reflecting the market's response to the company's developments and future potential [4][5]